Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3397768,tl/2 gamma,"The plasma pharmacokinetics were best described by a 3 compartment model, with a tl/2 gamma of 4.74 +/- 5.53 h.",Human central nervous system and plasma pharmacology of mitoxantrone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3397768/),h,4.74,4643,DB01204,Mitoxantrone
,6623546,elimination,"MX plasma decay curve at both doses could be fitted to a curve with three exponential components, with an average elimination (3rd component) half-life of about 3.5 h (1.5 mg/kg) and about 5 h (3 mg/kg), respectively.",Acute cardiovascular and renal changes induced by mitoxantrone in rabbits. A pharmacokinetic approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6623546/),h,3.5,7604,DB01204,Mitoxantrone
,6623546,elimination,"MX plasma decay curve at both doses could be fitted to a curve with three exponential components, with an average elimination (3rd component) half-life of about 3.5 h (1.5 mg/kg) and about 5 h (3 mg/kg), respectively.",Acute cardiovascular and renal changes induced by mitoxantrone in rabbits. A pharmacokinetic approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6623546/),h,5,7605,DB01204,Mitoxantrone
,20920295,AUC₀₋₇,"Mean AUC₀₋₇ (days) was 155.9 versus 152.4 mg*h/mL for Prolastin-C and Prolastin, respectively.",Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920295/),[h·mg] / [ml],155.9,10708,DB01204,Mitoxantrone
,20920295,AUC₀₋₇,"Mean AUC₀₋₇ (days) was 155.9 versus 152.4 mg*h/mL for Prolastin-C and Prolastin, respectively.",Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920295/),[h·mg] / [ml],152.4,10709,DB01204,Mitoxantrone
,9835899,Css plasma concentrations,"The Css plasma concentrations of ara-C and ara-U averaged 10.33 +/- 0.81 microM and 139.14 +/- 17.8 microM, respectively.",Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9835899/),μM,10.33,12079,DB01204,Mitoxantrone
,9835899,Css plasma concentrations,"The Css plasma concentrations of ara-C and ara-U averaged 10.33 +/- 0.81 microM and 139.14 +/- 17.8 microM, respectively.",Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9835899/),μM,139.14,12080,DB01204,Mitoxantrone
,22882086,Ki,"The MBLI87 Ki was estimated to 141 nm for Mit, 289 nm for CPT11, and 1160 nm for SN38.",A template model for studying anticancer drug efflux transporter inhibitors in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22882086/),nm,141,14354,DB01204,Mitoxantrone
,22882086,Ki,"The MBLI87 Ki was estimated to 141 nm for Mit, 289 nm for CPT11, and 1160 nm for SN38.",A template model for studying anticancer drug efflux transporter inhibitors in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22882086/),nm,289,14355,DB01204,Mitoxantrone
,22882086,Ki,"The MBLI87 Ki was estimated to 141 nm for Mit, 289 nm for CPT11, and 1160 nm for SN38.",A template model for studying anticancer drug efflux transporter inhibitors in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22882086/),nm,1160,14356,DB01204,Mitoxantrone
,22882086,ratio of intrinsic transport clearance divided by diffusion clearance,"The ratio of intrinsic transport clearance divided by diffusion clearance was estimated to 2.5 for Mit, 1.01 for CPT11, and 5.4 for SN38.",A template model for studying anticancer drug efflux transporter inhibitors in vitro. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22882086/),,2.5,14357,DB01204,Mitoxantrone
,22882086,ratio of intrinsic transport clearance divided by diffusion clearance,"The ratio of intrinsic transport clearance divided by diffusion clearance was estimated to 2.5 for Mit, 1.01 for CPT11, and 5.4 for SN38.",A template model for studying anticancer drug efflux transporter inhibitors in vitro. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22882086/),,1.01,14358,DB01204,Mitoxantrone
,22882086,ratio of intrinsic transport clearance divided by diffusion clearance,"The ratio of intrinsic transport clearance divided by diffusion clearance was estimated to 2.5 for Mit, 1.01 for CPT11, and 5.4 for SN38.",A template model for studying anticancer drug efflux transporter inhibitors in vitro. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22882086/),,5,14359,DB01204,Mitoxantrone
,2540217,t1/2 gamma,The terminal elimination half-lives measured in three patients (mean t1/2 gamma = 25 min) were all shorter than the published values which ranged from 56 min to 9 days.,High-performance liquid chromatographic determination of mitoxantrone in plasma utilizing non-bonded silica gel for solid-phase isolation to reduce adsorptive losses on glass during sample preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2540217/),min,25,17960,DB01204,Mitoxantrone
,2540217,t1/2 gamma,The terminal elimination half-lives measured in three patients (mean t1/2 gamma = 25 min) were all shorter than the published values which ranged from 56 min to 9 days.,High-performance liquid chromatographic determination of mitoxantrone in plasma utilizing non-bonded silica gel for solid-phase isolation to reduce adsorptive losses on glass during sample preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2540217/),min,56,17961,DB01204,Mitoxantrone
,2540217,t1/2 gamma,The terminal elimination half-lives measured in three patients (mean t1/2 gamma = 25 min) were all shorter than the published values which ranged from 56 min to 9 days.,High-performance liquid chromatographic determination of mitoxantrone in plasma utilizing non-bonded silica gel for solid-phase isolation to reduce adsorptive losses on glass during sample preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2540217/),d,9,17962,DB01204,Mitoxantrone
,8220130,Plas,Plasma protein binding of etoposide is extensive (94%) and alterations of the non-proteinbound fraction affect pharmacokinetic behavior of the drug.,In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),%,94,30213,DB01204,Mitoxantrone
,8220130,area under the concentration versus time curve AUC(0-infinity),The mean area under the concentration versus time curve AUC(0-infinity) in plasma was at the lower dose level 78.4 +/- 29.1 (mean +/- S.D.) micrograms/ml x h and 201.0 +/- 56.5 micrograms/ml x h at the higher dose level.,In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),[μg] / [h·ml],78.4,30214,DB01204,Mitoxantrone
,8220130,area under the concentration versus time curve AUC(0-infinity),The mean area under the concentration versus time curve AUC(0-infinity) in plasma was at the lower dose level 78.4 +/- 29.1 (mean +/- S.D.) micrograms/ml x h and 201.0 +/- 56.5 micrograms/ml x h at the higher dose level.,In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),[μg] / [h·ml],201.0,30215,DB01204,Mitoxantrone
,8220130,fraction of non-proteinbound,The fraction of non-proteinbound etoposide in plasma was 5.2 +/- 3.4 and 5.4 +/- 2.1% in the two treatment groups.,In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),%,5.2,30216,DB01204,Mitoxantrone
,8220130,fraction of non-proteinbound,The fraction of non-proteinbound etoposide in plasma was 5.2 +/- 3.4 and 5.4 +/- 2.1% in the two treatment groups.,In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),%,5.4,30217,DB01204,Mitoxantrone
,8220130,AUC(0-16h),"AUC(0-16h) in leukemic cells was 8.4 +/- 8.7 and 22.4 +/- 12.1 micrograms/ml x h at the two dose levels, respectively.",In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),[μg] / [h·ml],8.4,30218,DB01204,Mitoxantrone
,8220130,AUC(0-16h),"AUC(0-16h) in leukemic cells was 8.4 +/- 8.7 and 22.4 +/- 12.1 micrograms/ml x h at the two dose levels, respectively.",In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),[μg] / [h·ml],22.4,30219,DB01204,Mitoxantrone
,3767389,half-life,"With single administration, the blood concentrations showed that the half-life for the alpha phase was 0.16 h, for the beta phase 1.58 h, and for the gamma phase 83.4 h.",[Pharmacokinetic study of mitoxantrone]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767389/),h,0.16,36873,DB01204,Mitoxantrone
,3767389,half-life,"With single administration, the blood concentrations showed that the half-life for the alpha phase was 0.16 h, for the beta phase 1.58 h, and for the gamma phase 83.4 h.",[Pharmacokinetic study of mitoxantrone]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767389/),h,1.58,36874,DB01204,Mitoxantrone
,3767389,half-life,"With single administration, the blood concentrations showed that the half-life for the alpha phase was 0.16 h, for the beta phase 1.58 h, and for the gamma phase 83.4 h.",[Pharmacokinetic study of mitoxantrone]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767389/),h,83.4,36875,DB01204,Mitoxantrone
,3767389,distribution volume at steady state,"The distribution volume at steady state was 1,112 l/m2.",[Pharmacokinetic study of mitoxantrone]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767389/),[l] / [m2],"1,112",36876,DB01204,Mitoxantrone
,3767389,total body clearance,"The total body clearance was 326.8 ml/m2, showing rapid clearance from the blood.",[Pharmacokinetic study of mitoxantrone]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767389/),[ml] / [m2],326.8,36877,DB01204,Mitoxantrone
,7370981,initial plasma t1/2,"After i.v. administration of HAQ at 15 mg/kg (300 mg/sq m), the initial plasma t1/2 of the agent was 9.4 min, and the terminal t1/2 was 115.2 min.","Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370981/),min,9.4,46535,DB01204,Mitoxantrone
,7370981,terminal t1/2,"After i.v. administration of HAQ at 15 mg/kg (300 mg/sq m), the initial plasma t1/2 of the agent was 9.4 min, and the terminal t1/2 was 115.2 min.","Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370981/),min,115.2,46536,DB01204,Mitoxantrone
,7370981,maximal plasma concentration,A maximal plasma concentration of 24.9 mg of HAQ per liter was attained.,"Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370981/),mg,24.9,46537,DB01204,Mitoxantrone
,7370981,plasma clearance,A high plasma clearance of 23.5 ml/kg/min was observed in these animals.,"Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370981/),[ml] / [kg·min],23.5,46538,DB01204,Mitoxantrone
,7370981,apparent volume of distribution,"The extrapolated apparent volume of distribution was 693.7 ml/kg, comparable to that of antipyrine in the dog.","Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370981/),[ml] / [kg],693.7,46539,DB01204,Mitoxantrone
,8270970,Duration of neutropenia,Duration of neutropenia was longer for patients treated with 90 mg/m2 (31.7 days) than for patients treated with doses up to 75 mg/m2 (22.1 days) (P < .05).,"Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270970/),d,31.7,47385,DB01204,Mitoxantrone
,8270970,Duration of neutropenia,Duration of neutropenia was longer for patients treated with 90 mg/m2 (31.7 days) than for patients treated with doses up to 75 mg/m2 (22.1 days) (P < .05).,"Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270970/),d,22.1,47386,DB01204,Mitoxantrone
,29486258,EE,"The EE of MTO-mPEG-PENPs and MTO-PENPs were 99.02% and 98.33%, respectively.",Chitosan hydrochloride/hyaluronic acid nanoparticles coated by mPEG as long-circulating nanocarriers for systemic delivery of mitoxantrone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29486258/),%,99.02,48984,DB01204,Mitoxantrone
,29486258,EE,"The EE of MTO-mPEG-PENPs and MTO-PENPs were 99.02% and 98.33%, respectively.",Chitosan hydrochloride/hyaluronic acid nanoparticles coated by mPEG as long-circulating nanocarriers for systemic delivery of mitoxantrone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29486258/),%,98.33,48985,DB01204,Mitoxantrone
,29486258,MRT,The MRT of MTO increased from 117.83min (MTO solutions) and 162.34min (MTO-PENPs) to 344.42min (MTO-mPEG-PENPs).,Chitosan hydrochloride/hyaluronic acid nanoparticles coated by mPEG as long-circulating nanocarriers for systemic delivery of mitoxantrone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29486258/),min,117.83,48986,DB01204,Mitoxantrone
,29486258,MRT,The MRT of MTO increased from 117.83min (MTO solutions) and 162.34min (MTO-PENPs) to 344.42min (MTO-mPEG-PENPs).,Chitosan hydrochloride/hyaluronic acid nanoparticles coated by mPEG as long-circulating nanocarriers for systemic delivery of mitoxantrone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29486258/),min,162.34,48987,DB01204,Mitoxantrone
,29486258,MRT,The MRT of MTO increased from 117.83min (MTO solutions) and 162.34min (MTO-PENPs) to 344.42min (MTO-mPEG-PENPs).,Chitosan hydrochloride/hyaluronic acid nanoparticles coated by mPEG as long-circulating nanocarriers for systemic delivery of mitoxantrone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29486258/),min,344.42,48988,DB01204,Mitoxantrone
,3595257,peak plasma levels,"We have administered free M (30 mg/m2) or M mixed with poly(I).poly(C) (90 mg/m2) intraperitoneally to 5 patients with peritoneal carcinosis (cross-over study): peak plasma levels (HPLC assay) were 62 +/- 12 versus 28 +/- 4 ng/ml (p less than 0.0025), AUC0-24h were 583 +/- 126 versus 481 +/- 57 ng X h/ml (p less than 0.025).",Coupling of mitoxantrone to poly(I).poly(C) reduces absorption after intraperitoneal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595257/),[ng] / [ml],62,55156,DB01204,Mitoxantrone
,3595257,peak plasma levels,"We have administered free M (30 mg/m2) or M mixed with poly(I).poly(C) (90 mg/m2) intraperitoneally to 5 patients with peritoneal carcinosis (cross-over study): peak plasma levels (HPLC assay) were 62 +/- 12 versus 28 +/- 4 ng/ml (p less than 0.0025), AUC0-24h were 583 +/- 126 versus 481 +/- 57 ng X h/ml (p less than 0.025).",Coupling of mitoxantrone to poly(I).poly(C) reduces absorption after intraperitoneal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595257/),[ng] / [ml],28,55157,DB01204,Mitoxantrone
,3595257,AUC0-24h,"We have administered free M (30 mg/m2) or M mixed with poly(I).poly(C) (90 mg/m2) intraperitoneally to 5 patients with peritoneal carcinosis (cross-over study): peak plasma levels (HPLC assay) were 62 +/- 12 versus 28 +/- 4 ng/ml (p less than 0.0025), AUC0-24h were 583 +/- 126 versus 481 +/- 57 ng X h/ml (p less than 0.025).",Coupling of mitoxantrone to poly(I).poly(C) reduces absorption after intraperitoneal administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595257/),[h·ng] / [ml],583,55158,DB01204,Mitoxantrone
,3595257,AUC0-24h,"We have administered free M (30 mg/m2) or M mixed with poly(I).poly(C) (90 mg/m2) intraperitoneally to 5 patients with peritoneal carcinosis (cross-over study): peak plasma levels (HPLC assay) were 62 +/- 12 versus 28 +/- 4 ng/ml (p less than 0.0025), AUC0-24h were 583 +/- 126 versus 481 +/- 57 ng X h/ml (p less than 0.025).",Coupling of mitoxantrone to poly(I).poly(C) reduces absorption after intraperitoneal administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595257/),[h·ng] / [ml],481,55159,DB01204,Mitoxantrone
,8270975,Peak mitoxantrone levels,"Peak mitoxantrone levels at the MTD were 623 to 2,810 ng/mL, and the area under the curve (AUC) values of the concentration versus time measurements were 560 to 1,700 ng/mL/h.","Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270975/),[ng] / [ml],"623 to 2,810",56751,DB01204,Mitoxantrone
,8270975,area under the curve (AUC),"Peak mitoxantrone levels at the MTD were 623 to 2,810 ng/mL, and the area under the curve (AUC) values of the concentration versus time measurements were 560 to 1,700 ng/mL/h.","Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270975/),[ng] / [h·ml],"560 to 1,700",56752,DB01204,Mitoxantrone
,19834427,clearance,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),[l] / [h],23.1,59323,DB01204,Mitoxantrone
,19834427,central,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,35.4,59324,DB01204,Mitoxantrone
,19834427,peripheral volume of distribution,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,35.4,59325,DB01204,Mitoxantrone
,19834427,peripheral volume of distribution,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,1090,59326,DB01204,Mitoxantrone
,19834427,intercompartmental clearance,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,27.3,59327,DB01204,Mitoxantrone
,19834427,mean transit time (tau),"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),d,3.8,59328,DB01204,Mitoxantrone
,19834427,tau,"When patients had an early decrease in bilirubin at day 7, tau increased to 28.2 days.",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),d,28.2,59329,DB01204,Mitoxantrone
,16322302,maximal tolerated dose,"Dose-limiting toxicity occurred at 60 mg/m2/d with profound neutropenia >40 days duration, and maximal tolerated dose was 50 mg/m2/d.",Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322302/),[mg] / [d·m2],50,61138,DB01204,Mitoxantrone
,16322302,Overall response rate,Overall response rate was 31% in 26 acute myelogenous leukemia and 12.5% in acute lymphoblastic leukemia.,Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322302/),%,31,61139,DB01204,Mitoxantrone
,16322302,Overall response rate,Overall response rate was 31% in 26 acute myelogenous leukemia and 12.5% in acute lymphoblastic leukemia.,Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322302/),%,12.5,61140,DB01204,Mitoxantrone
,1802019,maximally tolerated dose (MTD),The maximally tolerated dose (MTD) was found to be 1.5 mg/m2/day.,A phase I trial of 14-day continuous intravenous infusion mitoxantrone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1802019/),[mg] / [d·m2],1.5,63988,DB01204,Mitoxantrone
,1802019,WBC,"At this dose four of six patients had grade III or IV leukopenia (mean WBC nadir 1900/microliters, range, 800-3600/microliters).",A phase I trial of 14-day continuous intravenous infusion mitoxantrone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1802019/),1/[μl],1900,63989,DB01204,Mitoxantrone
,1802019,nadir,"At this dose four of six patients had grade III or IV leukopenia (mean WBC nadir 1900/microliters, range, 800-3600/microliters).",A phase I trial of 14-day continuous intravenous infusion mitoxantrone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1802019/),1/[μl],1900,63990,DB01204,Mitoxantrone
,1802019,steady-state plasma concentration,"Steady-state plasma levels at the 1.5 mg/m2/day dose were reached by 48 h, with a mean steady-state plasma concentration of 3.2 +/- 0.7 ng/ml, mean total body clearance of 340 +/- 79 ml/min/m2, and mean area under the plasma disappearance curve (AUC) of 955 +/- 185 micrograms h/l.",A phase I trial of 14-day continuous intravenous infusion mitoxantrone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1802019/),[ng] / [ml],3.2,63991,DB01204,Mitoxantrone
,1802019,total body clearance,"Steady-state plasma levels at the 1.5 mg/m2/day dose were reached by 48 h, with a mean steady-state plasma concentration of 3.2 +/- 0.7 ng/ml, mean total body clearance of 340 +/- 79 ml/min/m2, and mean area under the plasma disappearance curve (AUC) of 955 +/- 185 micrograms h/l.",A phase I trial of 14-day continuous intravenous infusion mitoxantrone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1802019/),[ml] / [m2·min],340,63992,DB01204,Mitoxantrone
,1802019,area under the plasma disappearance curve (AUC),"Steady-state plasma levels at the 1.5 mg/m2/day dose were reached by 48 h, with a mean steady-state plasma concentration of 3.2 +/- 0.7 ng/ml, mean total body clearance of 340 +/- 79 ml/min/m2, and mean area under the plasma disappearance curve (AUC) of 955 +/- 185 micrograms h/l.",A phase I trial of 14-day continuous intravenous infusion mitoxantrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1802019/),[h·μg] / [l],955,63993,DB01204,Mitoxantrone
,12721757,blood concentration,VX-710 blood concentration at the time of mitoxantrone administration averaged 4.52 microg/ml.,"Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721757/),[μg] / [ml],4.52,67381,DB01204,Mitoxantrone
,12721757,time to PSA progression,The median time to PSA progression was 41 weeks (95% CI 34-68 weeks).,"Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721757/),weeks,41,67382,DB01204,Mitoxantrone
,4019115,terminal half-life,"The pharmacokinetic parameters are adequately described by a three-compartment model with a terminal half-life of 214.8 hours, and a volume of distribution (ss) of 3792 litres.",The pharmacokinetics and metabolism of mitoxantrone in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019115/),h,214.8,68410,DB01204,Mitoxantrone
,4019115,volume of distribution (ss),"The pharmacokinetic parameters are adequately described by a three-compartment model with a terminal half-life of 214.8 hours, and a volume of distribution (ss) of 3792 litres.",The pharmacokinetics and metabolism of mitoxantrone in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019115/),l,3792,68411,DB01204,Mitoxantrone
,4019115,total body clearance,The total body clearance was 358 ml/min and the renal clearance was 26.2 ml/min.,The pharmacokinetics and metabolism of mitoxantrone in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019115/),[ml] / [min],358,68412,DB01204,Mitoxantrone
,4019115,renal clearance,The total body clearance was 358 ml/min and the renal clearance was 26.2 ml/min.,The pharmacokinetics and metabolism of mitoxantrone in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019115/),[ml] / [min],26.2,68413,DB01204,Mitoxantrone
,23136195,OS,"Median OS was 12.2 versus 11.1 months [HR, 1.10; 80% confidence interval (CI), 0.82-1.48] in the combined rilotumumab versus control arms.",Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136195/),month,12.2,70846,DB01204,Mitoxantrone
,23136195,OS,"Median OS was 12.2 versus 11.1 months [HR, 1.10; 80% confidence interval (CI), 0.82-1.48] in the combined rilotumumab versus control arms.",Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136195/),month,11.1,70847,DB01204,Mitoxantrone
,23136195,progression-free survival,"Median progression-free survival was 3.0 versus 2.9 months (HR, 1.02; 80% CI, 0.79-1.31).",Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136195/),month,3.0,70848,DB01204,Mitoxantrone
,23136195,progression-free survival,"Median progression-free survival was 3.0 versus 2.9 months (HR, 1.02; 80% CI, 0.79-1.31).",Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136195/),month,2.9,70849,DB01204,Mitoxantrone
,9853980,CR rate,The CR rate after two courses with this regimen was 77%.,High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853980/),%,77,71027,DB01204,Mitoxantrone
,2545349,t1/2 alpha,"The plasma disappearance of mitoxantrone fitted into a three-compartment model with a mean t1/2 alpha of 10 min, a mean t1/2 beta of 96 min, and a slow elimination phase of 172 h.",High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2545349/),min,10,79036,DB01204,Mitoxantrone
,2545349,t1/2 beta,"The plasma disappearance of mitoxantrone fitted into a three-compartment model with a mean t1/2 alpha of 10 min, a mean t1/2 beta of 96 min, and a slow elimination phase of 172 h.",High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2545349/),min,96,79037,DB01204,Mitoxantrone
,2545349,distribution volume,The mean distribution volume was 4294 +/- 3836 liters.,High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2545349/),l,4294,79038,DB01204,Mitoxantrone
,11848489,entrapment efficiency,The liposome entrapment efficiency of mitoxantrone was 93.4 +/- 2.8%.,"Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848489/),%,93.4,85966,DB01204,Mitoxantrone
,11848489,IC50,"In vitro cytotoxicity studies in HL60 cells comparing LEM with conventional mitoxantrone (MTO) showed IC50 values of 0.31 +/- 0.05 ng/ml and 0.48 +/- 0.06 ng/ml for LEM and MTO, respectively.","Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848489/),[ng] / [ml],0.31,85967,DB01204,Mitoxantrone
,11848489,IC50,"In vitro cytotoxicity studies in HL60 cells comparing LEM with conventional mitoxantrone (MTO) showed IC50 values of 0.31 +/- 0.05 ng/ml and 0.48 +/- 0.06 ng/ml for LEM and MTO, respectively.","Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848489/),[ng] / [ml],0.48,85968,DB01204,Mitoxantrone
,11848489,plasma half-lives,"The plasma half-lives were 0.96 hours and 0.11 hours for LEM and MTO, respectively.","Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848489/),h,0.96,85969,DB01204,Mitoxantrone
,11848489,plasma half-lives,"The plasma half-lives were 0.96 hours and 0.11 hours for LEM and MTO, respectively.","Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11848489/),h,0.11,85970,DB01204,Mitoxantrone
,1829914,plasma plateau concentration,"A plasma plateau concentration of mitoxantrone (2.13 [S.D. 0.54] micrograms/1 at 2 mg/m2 per day, 2.56 [1.32] micrograms/1 at 2.2 per day and 3.46 [1.32] micrograms/l at 2.4 mg/m2 per day) was reached within 24-48 h.",Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829914/),μg,2.13,87538,DB01204,Mitoxantrone
,1829914,plasma plateau concentration,"A plasma plateau concentration of mitoxantrone (2.13 [S.D. 0.54] micrograms/1 at 2 mg/m2 per day, 2.56 [1.32] micrograms/1 at 2.2 per day and 3.46 [1.32] micrograms/l at 2.4 mg/m2 per day) was reached within 24-48 h.",Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829914/),μg,2.56,87539,DB01204,Mitoxantrone
,1829914,plasma plateau concentration,"A plasma plateau concentration of mitoxantrone (2.13 [S.D. 0.54] micrograms/1 at 2 mg/m2 per day, 2.56 [1.32] micrograms/1 at 2.2 per day and 3.46 [1.32] micrograms/l at 2.4 mg/m2 per day) was reached within 24-48 h.",Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829914/),[μg] / [l],3.46,87540,DB01204,Mitoxantrone
,1829914,plasma clearance,The mean plasma clearance of mitoxantrone was 27.8 [14.2] l/h/m2 and the volume of distribution of the beta phase averaged 2327 [2125] l/m2.,Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829914/),[l] / [h·m2],27.8,87541,DB01204,Mitoxantrone
,1829914,volume of distribution of the beta phase,The mean plasma clearance of mitoxantrone was 27.8 [14.2] l/h/m2 and the volume of distribution of the beta phase averaged 2327 [2125] l/m2.,Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829914/),[l] / [m2],2327,87542,DB01204,Mitoxantrone
,8988727,duration of complete remission,"The median duration of complete remission was 4 months (range, 1-14 months) whereas overall survival time lasted for a median of 4.5 months (range, 1-30+ months).",High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8988727/),month,4,87863,DB01204,Mitoxantrone
,8988727,overall survival time,"The median duration of complete remission was 4 months (range, 1-14 months) whereas overall survival time lasted for a median of 4.5 months (range, 1-30+ months).",High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8988727/),month,4.5,87864,DB01204,Mitoxantrone
,17093006,IC(50),"The flavonoid chrysin is a potent inhibitor of BCRP, inhibiting the efflux of mitoxantrone with an IC(50) of 0.39 microM in BCRP-overexpressing human MCF-7 breast cancer cells.",Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093006/),μM,0.39,97267,DB01204,Mitoxantrone
,17093006,AUC,"When nitrofurantoin (2 mg/kg) was given i.v., administration of chrysin (50 mg/kg i.p.) significantly increased the AUC of nitrofurantoin (123 +/- 34.0 versus 91.5 +/- 18.0 microg/ml x min in controls, p < 0.05).",Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093006/),[μg] / [min·ml],123,97268,DB01204,Mitoxantrone
,17093006,AUC,"When nitrofurantoin (2 mg/kg) was given i.v., administration of chrysin (50 mg/kg i.p.) significantly increased the AUC of nitrofurantoin (123 +/- 34.0 versus 91.5 +/- 18.0 microg/ml x min in controls, p < 0.05).",Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093006/),[μg] / [min·ml],91.5,97269,DB01204,Mitoxantrone
,3978648,specific activity,"Mitoxantrone (12 mg/sq m over 30 to 35 min in 250 ml of dextrose 5% in water) and 14C-labeled mitoxantrone (specific activity, 8.85 muCi/mg) were administered to eight patients who had advanced soft tissue cancers.",Disposition of mitoxantrone in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978648/),[muci] / [mg],8.85,98733,DB01204,Mitoxantrone
,3978648,t alpha,"The plasma disappearance of mitoxantrone concentrations measured by high-performance liquid chromatography was best described by a three-compartment model with a mean t alpha of 0.1 h, a t beta of 1.1 h, and a t gamma of 42.6 h.",Disposition of mitoxantrone in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978648/),h,0.1,98734,DB01204,Mitoxantrone
,3978648,t beta,"The plasma disappearance of mitoxantrone concentrations measured by high-performance liquid chromatography was best described by a three-compartment model with a mean t alpha of 0.1 h, a t beta of 1.1 h, and a t gamma of 42.6 h.",Disposition of mitoxantrone in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978648/),h,1.1,98735,DB01204,Mitoxantrone
,3978648,t gamma,"The plasma disappearance of mitoxantrone concentrations measured by high-performance liquid chromatography was best described by a three-compartment model with a mean t alpha of 0.1 h, a t beta of 1.1 h, and a t gamma of 42.6 h.",Disposition of mitoxantrone in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978648/),h,42.6,98736,DB01204,Mitoxantrone
,3978648,apparent Vc,"The mean apparent Vc was 12.2 liters/sq m, while the mean Vd was 1875 liters/sq m.",Disposition of mitoxantrone in cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978648/),[l] / [m·sq],12.2,98737,DB01204,Mitoxantrone
,3978648,Vd,"The mean apparent Vc was 12.2 liters/sq m, while the mean Vd was 1875 liters/sq m.",Disposition of mitoxantrone in cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978648/),[l] / [m·sq],1875,98738,DB01204,Mitoxantrone
,3978648,plasma clearance,"The mean plasma clearance was 0.57 liters/min/sq m, and the mean renal clearance was 45 ml/min/sq m.",Disposition of mitoxantrone in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978648/),[l] / [m·min·sq],0.57,98739,DB01204,Mitoxantrone
,3978648,renal clearance,"The mean plasma clearance was 0.57 liters/min/sq m, and the mean renal clearance was 45 ml/min/sq m.",Disposition of mitoxantrone in cancer patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978648/),[ml] / [m·min·sq],45,98740,DB01204,Mitoxantrone
,3978648,recovery,The mean recovery of 14C-labeled material in feces over 5 days was 18.3% of the administered dose.,Disposition of mitoxantrone in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978648/),%,18.3,98741,DB01204,Mitoxantrone
,2094639,T1/2,"The elimination of the drug was slow, T1/2 was 42.56 h.",[A study on pharmacokinetics of 3H-mitoxantrone in experimental animals]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2094639/),h,42.56,98932,DB01204,Mitoxantrone
,2094639,cumulative excretion,"In 72 h after administration the cumulative excretion of radioactivity in urine was 7% of the total dose, while that in feces was 43%.",[A study on pharmacokinetics of 3H-mitoxantrone in experimental animals]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2094639/),%,7,98933,DB01204,Mitoxantrone
,2094639,cumulative excretion,"In 72 h after administration the cumulative excretion of radioactivity in urine was 7% of the total dose, while that in feces was 43%.",[A study on pharmacokinetics of 3H-mitoxantrone in experimental animals]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2094639/),%,43,98934,DB01204,Mitoxantrone
,3552542,terminal half-life,Intravenously administered mitoxantrone disappears from the plasma of man and laboratory animals with multiexponential kinetics and with the terminal half-life ranging from 38 h to several days.,Pharmacokinetics of mitoxantrone in man and laboratory animals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552542/),h,38,102508,DB01204,Mitoxantrone
,3552542,terminal half-life,Intravenously administered mitoxantrone disappears from the plasma of man and laboratory animals with multiexponential kinetics and with the terminal half-life ranging from 38 h to several days.,Pharmacokinetics of mitoxantrone in man and laboratory animals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552542/),d,several,102509,DB01204,Mitoxantrone
,3791250,terminal half-life,The pharmacokinetic parameters are adequately described by a three-compartment model with a terminal half-life of 214.8 hours and a volume of distribution of 2248 L/m2.,Clinical pharmacology of mitoxantrone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791250/),h,214.8,105807,DB01204,Mitoxantrone
,3791250,volume of distribution,The pharmacokinetic parameters are adequately described by a three-compartment model with a terminal half-life of 214.8 hours and a volume of distribution of 2248 L/m2.,Clinical pharmacology of mitoxantrone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791250/),[l] / [m2],2248,105808,DB01204,Mitoxantrone
,3791250,total-body clearance,The total-body clearance was 217 ml/min/m2 and the renal clearance was 15 ml/min/m2.,Clinical pharmacology of mitoxantrone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791250/),[ml] / [m2·min],217,105809,DB01204,Mitoxantrone
,3791250,renal clearance,The total-body clearance was 217 ml/min/m2 and the renal clearance was 15 ml/min/m2.,Clinical pharmacology of mitoxantrone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791250/),[ml] / [m2·min],15,105810,DB01204,Mitoxantrone
,3757156,T1/2 alpha,"The time-concentration curves of i.v.-treated patients (15 mg/m2 over 30 min) correspond to a three-compartment model with a T1/2 alpha of 12 min, a T1/2 beta of 93 min, and a slow elimination phase of 36 h.",Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757156/),min,12,110106,DB01204,Mitoxantrone
,3757156,T1/2 beta,"The time-concentration curves of i.v.-treated patients (15 mg/m2 over 30 min) correspond to a three-compartment model with a T1/2 alpha of 12 min, a T1/2 beta of 93 min, and a slow elimination phase of 36 h.",Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757156/),min,93,110107,DB01204,Mitoxantrone
,3757156,slow elimination phase,"The time-concentration curves of i.v.-treated patients (15 mg/m2 over 30 min) correspond to a three-compartment model with a T1/2 alpha of 12 min, a T1/2 beta of 93 min, and a slow elimination phase of 36 h.",Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757156/),h,36,110108,DB01204,Mitoxantrone
,3757156,central compartment volume,"The central compartment volume was 26.22 and the distribution volume, 1381.9.",Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757156/),,26.22,110109,DB01204,Mitoxantrone
,3757156,distribution volume,"The central compartment volume was 26.22 and the distribution volume, 1381.9.",Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757156/),,1381.9,110110,DB01204,Mitoxantrone
,11432625,volume of distribution,"Pharmacokinetic analysis showed a large volume of distribution (13.5-17.5 l/kg), a high plasma clearance (0.65-1.74 l/h/kg) and a long elimination half-life (14.7-31.9 h).","Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432625/),[l] / [kg],13.5-17.5,110575,DB01204,Mitoxantrone
,11432625,plasma clearance,"Pharmacokinetic analysis showed a large volume of distribution (13.5-17.5 l/kg), a high plasma clearance (0.65-1.74 l/h/kg) and a long elimination half-life (14.7-31.9 h).","Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432625/),[l] / [h·kg],0.65-1.74,110576,DB01204,Mitoxantrone
,11432625,elimination half-life,"Pharmacokinetic analysis showed a large volume of distribution (13.5-17.5 l/kg), a high plasma clearance (0.65-1.74 l/h/kg) and a long elimination half-life (14.7-31.9 h).","Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432625/),h,14.7-31.9,110577,DB01204,Mitoxantrone
>,30077147,encapsulation efficiency,Maximum encapsulation efficiency (>95%) was observed at 40 mg/mL of PGMC or TPGS.,Mitoxantrone-loaded chitosan/hyaluronate polyelectrolyte nanoparticles decorated with amphiphilic PEG derivates for long-circulating effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077147/),%,95,113677,DB01204,Mitoxantrone
,2253652,Peak plasma concentrations,Peak plasma concentrations were 305 +/- 60 ng/ml at 2 h infusion and 244 +/- 89 ng/ml at 24 h infusion.,Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253652/),[ng] / [ml],305,124654,DB01204,Mitoxantrone
,2253652,Peak plasma concentrations,Peak plasma concentrations were 305 +/- 60 ng/ml at 2 h infusion and 244 +/- 89 ng/ml at 24 h infusion.,Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253652/),[ng] / [ml],244,124655,DB01204,Mitoxantrone
,2253652,elimination half-life,"No significant difference between both intra-arterial administrations in elimination half-life (50-223 h at 2 h infusion, 58-246 h at 24 h infusion) and area under the plasma concentration-time curve (AUC0-72 = 11.6 micrograms/ml.h for 2 h infusion, AUC0-72 = 11.2 micrograms/ml.h for 24 h infusion) could be found.",Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253652/),h,50-223,124656,DB01204,Mitoxantrone
,2253652,elimination half-life,"No significant difference between both intra-arterial administrations in elimination half-life (50-223 h at 2 h infusion, 58-246 h at 24 h infusion) and area under the plasma concentration-time curve (AUC0-72 = 11.6 micrograms/ml.h for 2 h infusion, AUC0-72 = 11.2 micrograms/ml.h for 24 h infusion) could be found.",Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253652/),h,58-246,124657,DB01204,Mitoxantrone
,2253652,area under the plasma concentration-time curve (AUC0-72,"No significant difference between both intra-arterial administrations in elimination half-life (50-223 h at 2 h infusion, 58-246 h at 24 h infusion) and area under the plasma concentration-time curve (AUC0-72 = 11.6 micrograms/ml.h for 2 h infusion, AUC0-72 = 11.2 micrograms/ml.h for 24 h infusion) could be found.",Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253652/),[μg] / [h·ml],11.6,124658,DB01204,Mitoxantrone
,2253652,AUC0-72,"No significant difference between both intra-arterial administrations in elimination half-life (50-223 h at 2 h infusion, 58-246 h at 24 h infusion) and area under the plasma concentration-time curve (AUC0-72 = 11.6 micrograms/ml.h for 2 h infusion, AUC0-72 = 11.2 micrograms/ml.h for 24 h infusion) could be found.",Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253652/),[μg] / [h·ml],11.2,124659,DB01204,Mitoxantrone
,9083333,maximum tolerated dose (MTD),"The dose administered was 90% of the maximum tolerated dose (MTD) of the corresponding formulation (8.1 micromol kg(-1) for free MTO, 12.1 micromol kg(-1) for PA-MTO and pH-MTO).",Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9083333/),μ,8.1,124673,DB01204,Mitoxantrone
,9083333,maximum tolerated dose (MTD),"The dose administered was 90% of the maximum tolerated dose (MTD) of the corresponding formulation (8.1 micromol kg(-1) for free MTO, 12.1 micromol kg(-1) for PA-MTO and pH-MTO).",Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9083333/),,12,124674,DB01204,Mitoxantrone
,12579808,mean residence time (MRT),"With the same dosage (2 mg.kg-1) i.v. in rabbits, the mean residence time (MRT) of the long circulating mitoxantrone liposomes was 9.8 h, while that of the normal liposomes was 3.6 h, and the AUC of the former is 6.4 fold greater than of the latter.",[Preparation of long circulating mitoxantrone liposomes and its pharmacokinetics]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579808/),h,9.8,129725,DB01204,Mitoxantrone
,12579808,mean residence time (MRT),"With the same dosage (2 mg.kg-1) i.v. in rabbits, the mean residence time (MRT) of the long circulating mitoxantrone liposomes was 9.8 h, while that of the normal liposomes was 3.6 h, and the AUC of the former is 6.4 fold greater than of the latter.",[Preparation of long circulating mitoxantrone liposomes and its pharmacokinetics]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579808/),h,3.6,129726,DB01204,Mitoxantrone
,3416898,ratio of area under curve,Pharmacokinetic analysis using high performance liquid chromatography yielded the following data: The mean ratio of area under curve peritoneal fluid to plasma was 1109.,Escalating dose regimen of intraperitoneal mitoxantrone: phase I study--clinical and pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416898/),,1109,130040,DB01204,Mitoxantrone
,3416898,peritoneal clearance rate,The peritoneal clearance rate was 680 ml/min and the mean disappearance half life was 13.1 h.,Escalating dose regimen of intraperitoneal mitoxantrone: phase I study--clinical and pharmacokinetic evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416898/),[ml] / [min],680,130041,DB01204,Mitoxantrone
,3416898,disappearance half life,The peritoneal clearance rate was 680 ml/min and the mean disappearance half life was 13.1 h.,Escalating dose regimen of intraperitoneal mitoxantrone: phase I study--clinical and pharmacokinetic evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416898/),h,13.1,130042,DB01204,Mitoxantrone
,8075031,maximum tolerable dose,"Sixty-seven cycles of mitoxantrone were administered, the maximum tolerable dose being 25 mg/m2.",Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8075031/),[mg] / [m2],25,132818,DB01204,Mitoxantrone
,4086246,apparent volume of distribution,"Ametantrone was extensively distributed (apparent volume of distribution, 26.3 l/m2) and demonstrated a short half-life (harmonic mean half-life, 0.38 hour).",A phase I trial of ametantrone acetate (NSC-287513). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4086246/),[l] / [m2],26.3,147468,DB01204,Mitoxantrone
,4086246,half-life,"Ametantrone was extensively distributed (apparent volume of distribution, 26.3 l/m2) and demonstrated a short half-life (harmonic mean half-life, 0.38 hour).",A phase I trial of ametantrone acetate (NSC-287513). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4086246/),h,0.38,147469,DB01204,Mitoxantrone
,4086246,maximum tolerated dose,The maximum tolerated dose in this study was 35 mg/m2.,A phase I trial of ametantrone acetate (NSC-287513). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4086246/),[mg] / [m2],35,147470,DB01204,Mitoxantrone
,9176748,survival,The median survival was 3 months (range 0.3-21.3 months).,Intrapleurally instilled mitoxantrone in metastatic pleural effusions: a phase II study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176748/),,3,147857,DB01204,Mitoxantrone
,1735075,terminal half-life,The pharmacokinetic parameters are described adequately by a three-compartment model with a terminal half-life of 71.5 +/- 40.1 hours and a volume of distribution of 5037 +/- 2377 l.,Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1735075/),h,71.5,149934,DB01204,Mitoxantrone
,1735075,volume of distribution,The pharmacokinetic parameters are described adequately by a three-compartment model with a terminal half-life of 71.5 +/- 40.1 hours and a volume of distribution of 5037 +/- 2377 l.,Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1735075/),l,5037,149935,DB01204,Mitoxantrone
,1735075,total plasma clearance,"The total plasma clearance was 743 +/- 462 ml/minute, and the renal clearance was 18.8 +/- 8.49 ml/minute.",Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1735075/),[ml] / [min],743,149936,DB01204,Mitoxantrone
,1735075,renal clearance,"The total plasma clearance was 743 +/- 462 ml/minute, and the renal clearance was 18.8 +/- 8.49 ml/minute.",Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1735075/),[ml] / [min],18.8,149937,DB01204,Mitoxantrone
,1735075,unbound fraction,"The values for unbound fraction (%) in plasma at time 0 and 5 minutes were 2.88 +/- 0.91% and 3.25 +/- 1.19%, with an average of 3.04 +/- 1.01%.",Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1735075/),%,2.88,149938,DB01204,Mitoxantrone
,1735075,unbound fraction,"The values for unbound fraction (%) in plasma at time 0 and 5 minutes were 2.88 +/- 0.91% and 3.25 +/- 1.19%, with an average of 3.04 +/- 1.01%.",Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1735075/),%,3.25,149939,DB01204,Mitoxantrone
,1735075,unbound fraction,"The values for unbound fraction (%) in plasma at time 0 and 5 minutes were 2.88 +/- 0.91% and 3.25 +/- 1.19%, with an average of 3.04 +/- 1.01%.",Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1735075/),%,3.04,149940,DB01204,Mitoxantrone
,3988457,specific radioactivity,Tritiated mitoxantrone of high specific radioactivity (ca. 15 Ci/mmol) was used as a radio-tracer ligand.,"Radioimmunoassay for mitoxantrone, a new antitumor agent. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988457/),[ci] / [mM],15,152046,DB01204,Mitoxantrone
,3988457,drug concentrations,The drug concentrations decreased from 32 ng/ml at 0.5 h to 0.45 ng/ml by 24 h after dosing.,"Radioimmunoassay for mitoxantrone, a new antitumor agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988457/),[ng] / [ml],32,152047,DB01204,Mitoxantrone
,3988457,drug concentrations,The drug concentrations decreased from 32 ng/ml at 0.5 h to 0.45 ng/ml by 24 h after dosing.,"Radioimmunoassay for mitoxantrone, a new antitumor agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988457/),[ng] / [ml],0.45,152048,DB01204,Mitoxantrone
,3988457,sensitivity,"The sensitivity of the currently available (HPLC) methods (5, 6) is of about 5-20 ng/ml in serum.","Radioimmunoassay for mitoxantrone, a new antitumor agent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988457/),[ng] / [ml],5-20,152049,DB01204,Mitoxantrone
,8402672,total body clearance,The plasma pharmacokinetics of mitoxantrone was linear between 15 and 90 mg/m2: total body clearance (19.3 +/- 6.2 liter/h/m2) and volume of distribution at steady state (486 +/- 254 liter/m2) were not altered by increasing the dose.,Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402672/),[l] / [h·m2],19.3,155501,DB01204,Mitoxantrone
,8402672,volume of distribution at steady state,The plasma pharmacokinetics of mitoxantrone was linear between 15 and 90 mg/m2: total body clearance (19.3 +/- 6.2 liter/h/m2) and volume of distribution at steady state (486 +/- 254 liter/m2) were not altered by increasing the dose.,Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402672/),[l] / [m2],486,155502,DB01204,Mitoxantrone
,8402672,area under the concentration +/- time curve ratio,"Whereas cellular versus plasma maximum concentration ratio was near 1, the area under the concentration +/- time curve ratio reached 100, suggesting a long elimination half-life from cells.",Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402672/),,100,155503,DB01204,Mitoxantrone
,26291333,EC50,"FD18 is a potent (EC50 = 148 nM for paclitaxel), safe (selective index = 574), and selective P-glycoprotein (P-gp) modulator.","A New Class of Safe, Potent, and Specific P-gp Modulator: Flavonoid Dimer FD18 Reverses P-gp-Mediated Multidrug Resistance in Human Breast Xenograft in Vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26291333/),nM,148,155958,DB01204,Mitoxantrone
,26291333,EC50,Pharmacokinetics studies indicated that intraperitoneal administration of 45 mg/kg FD18 was enough to maintain a plasma level above EC50 (148 nM) for more than 600 min.,"A New Class of Safe, Potent, and Specific P-gp Modulator: Flavonoid Dimer FD18 Reverses P-gp-Mediated Multidrug Resistance in Human Breast Xenograft in Vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26291333/),nM,148,155959,DB01204,Mitoxantrone
,20013854,systemic clearance,Mitoxantrone plasma concentrations exhibited a tri-exponential profile with systemic clearance of 118 +/- 6.8 mL/min/kg.,Pharmacokinetics and biliary excretion of mitoxantrone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20013854/),[ml] / [kg·min],118,157817,DB01204,Mitoxantrone
,20013854,CL(b),CL(b) was 7.20 +/- 4.54 and 7.46 +/- 0.62 mL/min/kg after the two doses.,Pharmacokinetics and biliary excretion of mitoxantrone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20013854/),[ml] / [kg·min],7.20,157818,DB01204,Mitoxantrone
,20013854,CL(b),CL(b) was 7.20 +/- 4.54 and 7.46 +/- 0.62 mL/min/kg after the two doses.,Pharmacokinetics and biliary excretion of mitoxantrone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20013854/),[ml] / [kg·min],7.46,157819,DB01204,Mitoxantrone
,20013854,CL(b),"Using QSPKR models developed for the biliary excretion of cations/neutral compounds in rats, CL(b) and PD(b) of mitoxantrone were predicted as 5.18 mL/min/kg and 7.21%, respectively, suggesting that the models could be used to predict the biliary excretion of mitoxantrone.",Pharmacokinetics and biliary excretion of mitoxantrone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20013854/),[ml] / [kg·min],5.18,157820,DB01204,Mitoxantrone
,20013854,PD(b),"Using QSPKR models developed for the biliary excretion of cations/neutral compounds in rats, CL(b) and PD(b) of mitoxantrone were predicted as 5.18 mL/min/kg and 7.21%, respectively, suggesting that the models could be used to predict the biliary excretion of mitoxantrone.",Pharmacokinetics and biliary excretion of mitoxantrone in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20013854/),%,7.21,157821,DB01204,Mitoxantrone
,18973800,release T(1/2),"The in vitro release T(1/2) values for the formulations were 15.0, 28.2 and 38.5h, respectively.",Ni2+-mediated mitoxantrone encapsulation: improved efficacy of fast release formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18973800/),h,15.0,158670,DB01204,Mitoxantrone
,18973800,release T(1/2),"The in vitro release T(1/2) values for the formulations were 15.0, 28.2 and 38.5h, respectively.",Ni2+-mediated mitoxantrone encapsulation: improved efficacy of fast release formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18973800/),h,28.2,158671,DB01204,Mitoxantrone
,18973800,release T(1/2),"The in vitro release T(1/2) values for the formulations were 15.0, 28.2 and 38.5h, respectively.",Ni2+-mediated mitoxantrone encapsulation: improved efficacy of fast release formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18973800/),h,38.5,158672,DB01204,Mitoxantrone
,11368437,maximum tolerated dose,The maximum tolerated dose of mitoxantrone was defined as 4.5 mg/m2/day.,"Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368437/),[mg] / [d·m2],4.5,161135,DB01204,Mitoxantrone
,11368437,overall survival,The median overall survival was 4 months.,"Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368437/),month,4,161136,DB01204,Mitoxantrone
,1558794,clearance,"In the first group of patients, mean +/- s.d. values of clearance, half-life and total distribution volume were 21.41 +/- 14.59 1 h-1, 19.83 +/- 23.95 h, 165.89 +/- 134.75 1 respectively.",Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1558794/),,21.41,167930,DB01204,Mitoxantrone
,1558794,total distribution volume,"In the first group of patients, mean +/- s.d. values of clearance, half-life and total distribution volume were 21.41 +/- 14.59 1 h-1, 19.83 +/- 23.95 h, 165.89 +/- 134.75 1 respectively.",Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1558794/),h,23.95,167931,DB01204,Mitoxantrone
,1558794,total distribution volume,"In the first group of patients, mean +/- s.d. values of clearance, half-life and total distribution volume were 21.41 +/- 14.59 1 h-1, 19.83 +/- 23.95 h, 165.89 +/- 134.75 1 respectively.",Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1558794/),,165.89,167932,DB01204,Mitoxantrone
,1558794,half-life,The half-life is long for patients receiving high-dose mitoxantrone (mean value was 50 h) and it would be hazardous to perform BMT too early after mitoxantrone infusion.,Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1558794/),h,50,167933,DB01204,Mitoxantrone
,18573336,half-life,"When the formulations were injected into BDF1 mice at a dose of 4 mg/kg, all the liposomal formulations exhibited enhanced blood circulation time, with half-life values of 6.8-7.2h, significantly compared to the rapid clearance of free-MIT.","Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18573336/),h,6.8-7.2,168215,DB01204,Mitoxantrone
,18573336,survival time,"At a dose of 6 mg/kg, the treatment with CuCl(2) formulation resulted in a median survival time of 21 days, considerably larger than that of CuSO(4) groups (15 days).","Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18573336/),d,21,168216,DB01204,Mitoxantrone
,18573336,survival time,"At a dose of 6 mg/kg, the treatment with CuCl(2) formulation resulted in a median survival time of 21 days, considerably larger than that of CuSO(4) groups (15 days).","Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18573336/),d,15,168217,DB01204,Mitoxantrone
,3295627,peritoneal clearance,"The peritoneal clearance ranged from 2 ml/min to 9,617 ml/min and the disappearance half-life from 0.6-28.9 h.",Phase-I study of intraperitoneal mitoxantrone--clinical and pharmacokinetic evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3295627/),[ml] / [min],2,170273,DB01204,Mitoxantrone
,3295627,peritoneal clearance,"The peritoneal clearance ranged from 2 ml/min to 9,617 ml/min and the disappearance half-life from 0.6-28.9 h.",Phase-I study of intraperitoneal mitoxantrone--clinical and pharmacokinetic evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3295627/),[ml] / [min],"9,617",170274,DB01204,Mitoxantrone
,3295627,disappearance half-life,"The peritoneal clearance ranged from 2 ml/min to 9,617 ml/min and the disappearance half-life from 0.6-28.9 h.",Phase-I study of intraperitoneal mitoxantrone--clinical and pharmacokinetic evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3295627/),h,0.6-28.9,170275,DB01204,Mitoxantrone
,28174232,fraction unbound,Flavopiridol fraction unbound was 10.9% and not different between schedules.,Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174232/),%,10.9,171040,DB01204,Mitoxantrone
≥,28174232,AUC,"Clinical response was associated with AUC ≥ 780 h*ng/mL for newly diagnosed patients and AUC ≥ 1,690 h*ng/mL for relapsed/refractory patients.",Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174232/),[h·ng] / [ml],780,171041,DB01204,Mitoxantrone
≥,28174232,AUC,"Clinical response was associated with AUC ≥ 780 h*ng/mL for newly diagnosed patients and AUC ≥ 1,690 h*ng/mL for relapsed/refractory patients.",Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174232/),[h·ng] / [ml],"1,690",171042,DB01204,Mitoxantrone
,22796159,encapsulation efficiency,"The mitoxantrone (MX) loaded LPG (MX-LPG) was about 100 nm in diameter, spherically shaped, and had an encapsulation efficiency of 97.3%.",Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22796159/),%,97.3,171120,DB01204,Mitoxantrone
,15671557,survival,Median survival was 14.6 months.,"A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671557/),month,14.6,171334,DB01204,Mitoxantrone
,20209646,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) of valspodar was 12.5 mg/kg/day, combined with 50% dose-reduced mitoxantrone and etoposide.",Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20209646/),[mg] / [d·kg],12.5,173804,DB01204,Mitoxantrone
,12016932,expansion ratio,"The results showed that the average diameter of the DHAQ-CMS-MS was 75.71 microns, drug loading was 13.21%, expansion ratio in water was 71.94%.",[Study on the mitoxantrone carboxymethyl starch microspheres for hepatic artery chemoembolization]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016932/),%,71.94,179440,DB01204,Mitoxantrone
,8998559,extraction efficiencies,The extraction efficiencies of MTO are 60% in whole blood and 38% in tissue homogenates.,Determination of mitoxantrone in mouse whole blood and different tissues by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8998559/),%,60,184524,DB01204,Mitoxantrone
,8998559,extraction efficiencies,The extraction efficiencies of MTO are 60% in whole blood and 38% in tissue homogenates.,Determination of mitoxantrone in mouse whole blood and different tissues by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8998559/),%,38,184525,DB01204,Mitoxantrone
,10854132,Cmax,"Maximal mitoxantrone plasma concentrations (Cmax), times to Cmax (Tpeak) and area under the curves (AUC) were highly variable between subjects (Cmax 14-337 ng/ml; Tpeak 0.5-8 h; AUC 222-4130 ng x ml(-1) x h).",Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10854132/),[ng] / [ml],14-337,187641,DB01204,Mitoxantrone
,10854132,Tpeak,"Maximal mitoxantrone plasma concentrations (Cmax), times to Cmax (Tpeak) and area under the curves (AUC) were highly variable between subjects (Cmax 14-337 ng/ml; Tpeak 0.5-8 h; AUC 222-4130 ng x ml(-1) x h).",Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10854132/),h,0.5-8,187642,DB01204,Mitoxantrone
,10854132,AUC,"Maximal mitoxantrone plasma concentrations (Cmax), times to Cmax (Tpeak) and area under the curves (AUC) were highly variable between subjects (Cmax 14-337 ng/ml; Tpeak 0.5-8 h; AUC 222-4130 ng x ml(-1) x h).",Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10854132/),[h·ng] / [ml],222-4130,187643,DB01204,Mitoxantrone
,10854132,plasma to peritoneal fluid AUC ratio,"The plasma to peritoneal fluid AUC ratio was significantly higher during the second (0.177) than during the first cycle (0.066), suggesting a cycle-dependent increase in systemic bioavailability.",Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10854132/),,0.177,187644,DB01204,Mitoxantrone
,10854132,plasma to peritoneal fluid AUC ratio,"The plasma to peritoneal fluid AUC ratio was significantly higher during the second (0.177) than during the first cycle (0.066), suggesting a cycle-dependent increase in systemic bioavailability.",Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10854132/),,0.066,187645,DB01204,Mitoxantrone
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,4.3,188010,DB01204,Mitoxantrone
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,3.6,188011,DB01204,Mitoxantrone
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,1.9,188012,DB01204,Mitoxantrone
,7913721,progression-free,"With a median potential follow-up duration of 60 weeks, the median progression-free and overall survival durations were 27 and 43 weeks, respectively.",Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913721/),weeks,27,188629,DB01204,Mitoxantrone
more,7913721,serum steady-state concentrations (Css),"Paclitaxel pharmacokinetics showed a correlation between both granulocyte and mucosal toxicity, and serum steady-state concentrations (Css) more than 0.07 mumol/L.",Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913721/),[μM] / [l],0.07,188630,DB01204,Mitoxantrone
,8157471,MTD,"Therefore, we conclude the MTD was 37 mg/m2/day.",Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157471/),[mg] / [d·m2],37,189231,DB01204,Mitoxantrone
,8410125,time to complete remission (CR),"Myelosuppression was universal and the median time to complete remission (CR) was 28 days (range, 19 to 77).",Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410125/),d,28,191834,DB01204,Mitoxantrone
,2084130,lower detection limit,The lower detection limit of this assay method was 1 ng.,"Novel assay method for mitoxantrone in plasma, and its application in cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2084130/),ng,1,193439,DB01204,Mitoxantrone
,33667664,IC50,"In previous studies, MTO-loaded estrogen receptor targeted and sterically stabilized liposome (ES-SSL-MTO; ES: estrone, is known to bind the ER) had been synthesized and showed a very high antiproliferative effect with IC50 value of 0.7 ng/mL.","Estrone-targeted liposomes for mitoxantrone delivery via estrogen receptor: In vivo targeting efficacy, antitumor activity, acute toxicity and pharmacokinetics. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33667664/),[ng] / [ml],0.7,195446,DB01204,Mitoxantrone
,18766965,MTD,The duration of MTD for gemcitabine was 12 h.,"Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18766965/),h,12,195846,DB01204,Mitoxantrone
,1760859,t1/2 alpha,"The mean half-lives for mitoxantrone in the blood circulation of the leg were: t1/2 alpha (distribution phase), 25.5 s, and t1/2 beta (elimination phase), 14.9 min.","Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1760859/),s,25.5,201331,DB01204,Mitoxantrone
,1760859,t1/2 beta (elimination phase),"The mean half-lives for mitoxantrone in the blood circulation of the leg were: t1/2 alpha (distribution phase), 25.5 s, and t1/2 beta (elimination phase), 14.9 min.","Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1760859/),min,14.9,201332,DB01204,Mitoxantrone
,1760859,volume of distribution at steady state,The mean volume of distribution at steady state in the leg was 25.6 1.,"Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1760859/),1,25.6,201333,DB01204,Mitoxantrone
,1760859,AUC,"In the arterial part of the perfusion, the mean AUC was 155.9 mg min l-1, and that in the corresponding venous part was 91.6 mg min l-1.","Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1760859/),[mg·min] / [l],155.9,201334,DB01204,Mitoxantrone
,1760859,AUC,"In the arterial part of the perfusion, the mean AUC was 155.9 mg min l-1, and that in the corresponding venous part was 91.6 mg min l-1.","Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1760859/),[mg·min] / [l],91.6,201335,DB01204,Mitoxantrone
,1760859,elimination half-life,The mean elimination half-life of mitoxantrone in the systemic circulation was 123 min and the corresponding AUC for systemic concentrations was 8.59 mg min l-1.,"Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1760859/),min,123,201336,DB01204,Mitoxantrone
,1760859,AUC,The mean elimination half-life of mitoxantrone in the systemic circulation was 123 min and the corresponding AUC for systemic concentrations was 8.59 mg min l-1.,"Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1760859/),[mg·min] / [l],8.59,201337,DB01204,Mitoxantrone
,10964334,T(1/2),"Doxil pharmacokinetics was well described by a monoexponential elimination curve with a long T(1/2) (median, 79 hours), a slow clearance (median, 40 mL/hour), and a small volume of distribution (median, 3.9 L).",Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10964334/),h,79,203174,DB01204,Mitoxantrone
,10964334,clearance,"Doxil pharmacokinetics was well described by a monoexponential elimination curve with a long T(1/2) (median, 79 hours), a slow clearance (median, 40 mL/hour), and a small volume of distribution (median, 3.9 L).",Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10964334/),[ml] / [h],40,203175,DB01204,Mitoxantrone
,10964334,volume of distribution,"Doxil pharmacokinetics was well described by a monoexponential elimination curve with a long T(1/2) (median, 79 hours), a slow clearance (median, 40 mL/hour), and a small volume of distribution (median, 3.9 L).",Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10964334/),l,3.9,203176,DB01204,Mitoxantrone
,20643587,flow rate,The chromatographic separation was achieved within 2.5min using methanol-10mM ammonium acetate containing 0.1% acetic acid as the mobile phase at a flow rate of 0.2mL/min.,Determination of mitoxantrone in rat plasma by liquid chromatography-tandem mass spectrometry method: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643587/),[ml] / [min],0.2,205105,DB01204,Mitoxantrone
,10784627,remission rate,The remission rate was 35% (n = 23 of 66).,"Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784627/),%,35,214903,DB01204,Mitoxantrone
,17290615,release time,The release time of VCR from compound liposome was 24 h and that from free drug (in control solution) was 6 h.,[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,24,215174,DB01204,Mitoxantrone
,17290615,release time,The release time of VCR from compound liposome was 24 h and that from free drug (in control solution) was 6 h.,[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,6,215175,DB01204,Mitoxantrone
,17290615,release time,The release of MTO from compound liposome was 0.05% after 288 h and release time of MTO from free drug (in control solution) was 12 h.,[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,12,215176,DB01204,Mitoxantrone
,17290615,elimination half-life time (T 1/2),"The elimination half-life time (T 1/2) in plasma of liposomal and free VCR were 0.16 h and 0.14 h, and the AUCs (0 - 48 h) of them were 2.69 (ug x g(-1)) x h and 1.58 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,0.16,215177,DB01204,Mitoxantrone
,17290615,elimination half-life time (T 1/2),"The elimination half-life time (T 1/2) in plasma of liposomal and free VCR were 0.16 h and 0.14 h, and the AUCs (0 - 48 h) of them were 2.69 (ug x g(-1)) x h and 1.58 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,0.14,215178,DB01204,Mitoxantrone
,17290615,AUCs (0 - 48 h),"The elimination half-life time (T 1/2) in plasma of liposomal and free VCR were 0.16 h and 0.14 h, and the AUCs (0 - 48 h) of them were 2.69 (ug x g(-1)) x h and 1.58 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),[h·ug] / [g],2.69,215179,DB01204,Mitoxantrone
,17290615,AUCs (0 - 48 h),"The elimination half-life time (T 1/2) in plasma of liposomal and free VCR were 0.16 h and 0.14 h, and the AUCs (0 - 48 h) of them were 2.69 (ug x g(-1)) x h and 1.58 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),[h·ug] / [g],1.58,215180,DB01204,Mitoxantrone
,17290615,elimination half-life times (T 1/2),"The elimination half-life times (T 1/2) in plasma of liposomal and free MTO were 21.6 h and 0.05 h and the AUCs (0 - 48 h) of them were 17.06 (ug x g(-1)) x h and 0.42 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,21.6,215181,DB01204,Mitoxantrone
,17290615,elimination half-life times (T 1/2),"The elimination half-life times (T 1/2) in plasma of liposomal and free MTO were 21.6 h and 0.05 h and the AUCs (0 - 48 h) of them were 17.06 (ug x g(-1)) x h and 0.42 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,0.05,215182,DB01204,Mitoxantrone
,17290615,AUCs (0 - 48 h),"The elimination half-life times (T 1/2) in plasma of liposomal and free MTO were 21.6 h and 0.05 h and the AUCs (0 - 48 h) of them were 17.06 (ug x g(-1)) x h and 0.42 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),[h·ug] / [g],17.06,215183,DB01204,Mitoxantrone
,17290615,AUCs (0 - 48 h),"The elimination half-life times (T 1/2) in plasma of liposomal and free MTO were 21.6 h and 0.05 h and the AUCs (0 - 48 h) of them were 17.06 (ug x g(-1)) x h and 0.42 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),[h·ug] / [g],0.42,215184,DB01204,Mitoxantrone
,2912555,maximum biliary concentration,"Biliary excretion was very rapid (maximum biliary concentration achieved 9 to 18 min following drug administration) and amounted to 29.5 +/- 9.3%, 27.6 +/- 7.9%, and 28.3 +/- 3.8% of administered drug, respectively.",Excretion and metabolism of mitoxantrone in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2912555/),%,29.5,216569,DB01204,Mitoxantrone
,2912555,maximum biliary concentration,"Biliary excretion was very rapid (maximum biliary concentration achieved 9 to 18 min following drug administration) and amounted to 29.5 +/- 9.3%, 27.6 +/- 7.9%, and 28.3 +/- 3.8% of administered drug, respectively.",Excretion and metabolism of mitoxantrone in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2912555/),%,27.6,216570,DB01204,Mitoxantrone
,2912555,maximum biliary concentration,"Biliary excretion was very rapid (maximum biliary concentration achieved 9 to 18 min following drug administration) and amounted to 29.5 +/- 9.3%, 27.6 +/- 7.9%, and 28.3 +/- 3.8% of administered drug, respectively.",Excretion and metabolism of mitoxantrone in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2912555/),%,28.3,216571,DB01204,Mitoxantrone
,2912555,Urinary excretion,"Urinary excretion amounted to 7.3 +/- 0.2%, 7.1 +/- 4.6%, and 6.0 +/- 1.5%, respectively.",Excretion and metabolism of mitoxantrone in rabbits. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2912555/),%,7.3,216572,DB01204,Mitoxantrone
,2912555,Urinary excretion,"Urinary excretion amounted to 7.3 +/- 0.2%, 7.1 +/- 4.6%, and 6.0 +/- 1.5%, respectively.",Excretion and metabolism of mitoxantrone in rabbits. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2912555/),%,7.1,216573,DB01204,Mitoxantrone
,2912555,Urinary excretion,"Urinary excretion amounted to 7.3 +/- 0.2%, 7.1 +/- 4.6%, and 6.0 +/- 1.5%, respectively.",Excretion and metabolism of mitoxantrone in rabbits. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2912555/),%,6.0,216574,DB01204,Mitoxantrone
,1568292,t1/2 beta (distribution),"Median values obtained for the pharmacokinetic parameters of mitoxantrone in peritoneal dialysate were: t1/2 beta (distribution), 56.4 min (range, 16.8-235.8 min); t1/2 gamma (elimination), 128 h (range, 28.3-171.0 h); Vdss (volume of distribution at steady state), 24.8 l (range, 17.0-232.5 l); delta'ss (volume of distribution at steady state corrected for the body surface area in square meters), 14.4 l/m2 (range, 10.6-129.2 l/m2); and clearance, 0.25 l/h (range, 0.16-0.59 l/h).",Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568292/),min,56.4,222505,DB01204,Mitoxantrone
,1568292,t1/2 gamma (elimination),"Median values obtained for the pharmacokinetic parameters of mitoxantrone in peritoneal dialysate were: t1/2 beta (distribution), 56.4 min (range, 16.8-235.8 min); t1/2 gamma (elimination), 128 h (range, 28.3-171.0 h); Vdss (volume of distribution at steady state), 24.8 l (range, 17.0-232.5 l); delta'ss (volume of distribution at steady state corrected for the body surface area in square meters), 14.4 l/m2 (range, 10.6-129.2 l/m2); and clearance, 0.25 l/h (range, 0.16-0.59 l/h).",Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568292/),h,128,222506,DB01204,Mitoxantrone
,1568292,Vdss (volume of distribution at steady state,"Median values obtained for the pharmacokinetic parameters of mitoxantrone in peritoneal dialysate were: t1/2 beta (distribution), 56.4 min (range, 16.8-235.8 min); t1/2 gamma (elimination), 128 h (range, 28.3-171.0 h); Vdss (volume of distribution at steady state), 24.8 l (range, 17.0-232.5 l); delta'ss (volume of distribution at steady state corrected for the body surface area in square meters), 14.4 l/m2 (range, 10.6-129.2 l/m2); and clearance, 0.25 l/h (range, 0.16-0.59 l/h).",Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568292/),l,24.8,222507,DB01204,Mitoxantrone
,1568292,delta'ss,"Median values obtained for the pharmacokinetic parameters of mitoxantrone in peritoneal dialysate were: t1/2 beta (distribution), 56.4 min (range, 16.8-235.8 min); t1/2 gamma (elimination), 128 h (range, 28.3-171.0 h); Vdss (volume of distribution at steady state), 24.8 l (range, 17.0-232.5 l); delta'ss (volume of distribution at steady state corrected for the body surface area in square meters), 14.4 l/m2 (range, 10.6-129.2 l/m2); and clearance, 0.25 l/h (range, 0.16-0.59 l/h).",Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568292/),[l] / [m2],14.4,222508,DB01204,Mitoxantrone
,1568292,volume of distribution at steady state,"Median values obtained for the pharmacokinetic parameters of mitoxantrone in peritoneal dialysate were: t1/2 beta (distribution), 56.4 min (range, 16.8-235.8 min); t1/2 gamma (elimination), 128 h (range, 28.3-171.0 h); Vdss (volume of distribution at steady state), 24.8 l (range, 17.0-232.5 l); delta'ss (volume of distribution at steady state corrected for the body surface area in square meters), 14.4 l/m2 (range, 10.6-129.2 l/m2); and clearance, 0.25 l/h (range, 0.16-0.59 l/h).",Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568292/),[l] / [m2],14.4,222509,DB01204,Mitoxantrone
,1568292,clearance,"Median values obtained for the pharmacokinetic parameters of mitoxantrone in peritoneal dialysate were: t1/2 beta (distribution), 56.4 min (range, 16.8-235.8 min); t1/2 gamma (elimination), 128 h (range, 28.3-171.0 h); Vdss (volume of distribution at steady state), 24.8 l (range, 17.0-232.5 l); delta'ss (volume of distribution at steady state corrected for the body surface area in square meters), 14.4 l/m2 (range, 10.6-129.2 l/m2); and clearance, 0.25 l/h (range, 0.16-0.59 l/h).",Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568292/),[l] / [h],0.25,222510,DB01204,Mitoxantrone
,1568292,t1/2 alpha (absorption),"For plasma the median values were: t1/2 alpha (absorption), 58.8 min (range, 45.6-87.0 min); t1/2 beta (distribution), 2.5 h (range, 1.4-6.3 h); t1/2 gamma (elimination), 44.1 h (range, 9.1-91 h); Vdss, 2,152 l (range, 352-19,733 l); delta'ss, 1,345 l/m2 (range, 220-11,606 l/m2); and clearance, 117 l/h (range, 51-1,609 l/h).",Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568292/),min,58.8,222511,DB01204,Mitoxantrone
,1568292,t1/2 beta (distribution),"For plasma the median values were: t1/2 alpha (absorption), 58.8 min (range, 45.6-87.0 min); t1/2 beta (distribution), 2.5 h (range, 1.4-6.3 h); t1/2 gamma (elimination), 44.1 h (range, 9.1-91 h); Vdss, 2,152 l (range, 352-19,733 l); delta'ss, 1,345 l/m2 (range, 220-11,606 l/m2); and clearance, 117 l/h (range, 51-1,609 l/h).",Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568292/),h,2.5,222512,DB01204,Mitoxantrone
,1568292,t1/2 gamma (elimination),"For plasma the median values were: t1/2 alpha (absorption), 58.8 min (range, 45.6-87.0 min); t1/2 beta (distribution), 2.5 h (range, 1.4-6.3 h); t1/2 gamma (elimination), 44.1 h (range, 9.1-91 h); Vdss, 2,152 l (range, 352-19,733 l); delta'ss, 1,345 l/m2 (range, 220-11,606 l/m2); and clearance, 117 l/h (range, 51-1,609 l/h).",Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568292/),h,44.1,222513,DB01204,Mitoxantrone
,1568292,Vdss,"For plasma the median values were: t1/2 alpha (absorption), 58.8 min (range, 45.6-87.0 min); t1/2 beta (distribution), 2.5 h (range, 1.4-6.3 h); t1/2 gamma (elimination), 44.1 h (range, 9.1-91 h); Vdss, 2,152 l (range, 352-19,733 l); delta'ss, 1,345 l/m2 (range, 220-11,606 l/m2); and clearance, 117 l/h (range, 51-1,609 l/h).",Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568292/),l,"2,152",222514,DB01204,Mitoxantrone
,1568292,delta'ss,"For plasma the median values were: t1/2 alpha (absorption), 58.8 min (range, 45.6-87.0 min); t1/2 beta (distribution), 2.5 h (range, 1.4-6.3 h); t1/2 gamma (elimination), 44.1 h (range, 9.1-91 h); Vdss, 2,152 l (range, 352-19,733 l); delta'ss, 1,345 l/m2 (range, 220-11,606 l/m2); and clearance, 117 l/h (range, 51-1,609 l/h).",Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568292/),[l] / [m2],"1,345",222515,DB01204,Mitoxantrone
,1568292,clearance,"For plasma the median values were: t1/2 alpha (absorption), 58.8 min (range, 45.6-87.0 min); t1/2 beta (distribution), 2.5 h (range, 1.4-6.3 h); t1/2 gamma (elimination), 44.1 h (range, 9.1-91 h); Vdss, 2,152 l (range, 352-19,733 l); delta'ss, 1,345 l/m2 (range, 220-11,606 l/m2); and clearance, 117 l/h (range, 51-1,609 l/h).",Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568292/),[l] / [h],117,222516,DB01204,Mitoxantrone
,1568292,plasma concentration,After 168 h the median plasma concentration was 1 ng/ml.,Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568292/),[ng] / [ml],1,222517,DB01204,Mitoxantrone
,1568292,peak concentration,The median peak concentration in peritoneal dialysate was 490 ng/ml.,Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568292/),[ng] / [ml],490,222518,DB01204,Mitoxantrone
,22451016,binding,"The estimated binding affinity for DNA (K (DNA)) and protein (K (macro)) were 0.0013 and 1.44 μM, respectively.",A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451016/),μM,0.0013,222971,DB01204,Mitoxantrone
,22451016,K (DNA),"The estimated binding affinity for DNA (K (DNA)) and protein (K (macro)) were 0.0013 and 1.44 μM, respectively.",A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451016/),μM,0.0013,222972,DB01204,Mitoxantrone
,22451016,K (macro)),"The estimated binding affinity for DNA (K (DNA)) and protein (K (macro)) were 0.0013 and 1.44 μM, respectively.",A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451016/),μM,0.0013,222973,DB01204,Mitoxantrone
,22451016,K (macro)),"The estimated binding affinity for DNA (K (DNA)) and protein (K (macro)) were 0.0013 and 1.44 μM, respectively.",A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451016/),μM,1.44,222974,DB01204,Mitoxantrone
,2600798,clearance,"Population mean values (+/- interindividual SD) of clearance, terminal half-life, and total volume of distribution were, respectively, 23.40 (+/- 10.76) L/h, 46.87 (+/- 12.18) h, and 385.49 (+/- 196.60) L.",Population pharmacokinetics of mitoxantrone performed by a NONMEM method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600798/),[l] / [h],23.40,237147,DB01204,Mitoxantrone
,2600798,terminal half-life,"Population mean values (+/- interindividual SD) of clearance, terminal half-life, and total volume of distribution were, respectively, 23.40 (+/- 10.76) L/h, 46.87 (+/- 12.18) h, and 385.49 (+/- 196.60) L.",Population pharmacokinetics of mitoxantrone performed by a NONMEM method. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600798/),h,46.87,237148,DB01204,Mitoxantrone
,2600798,total volume of distribution,"Population mean values (+/- interindividual SD) of clearance, terminal half-life, and total volume of distribution were, respectively, 23.40 (+/- 10.76) L/h, 46.87 (+/- 12.18) h, and 385.49 (+/- 196.60) L.",Population pharmacokinetics of mitoxantrone performed by a NONMEM method. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600798/),l,385.49,237149,DB01204,Mitoxantrone
,2185907,absorption half-life,"All studies reported a short absorption half-life of between 4.1 and 10.7 minutes, with the distribution phase being between 0.3 and 3.1 hours.",Pharmacokinetics and metabolism of mitoxantrone. A review. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185907/),min,4.1 and 10.7,240393,DB01204,Mitoxantrone
,2185907,distribution phase,"All studies reported a short absorption half-life of between 4.1 and 10.7 minutes, with the distribution phase being between 0.3 and 3.1 hours.",Pharmacokinetics and metabolism of mitoxantrone. A review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185907/),h,0.3 and 3.1,240394,DB01204,Mitoxantrone
,2185907,terminal half-life,"In contrast, the values of the terminal half-life are quite variable, ranging from 8.9 hours to 9 days.",Pharmacokinetics and metabolism of mitoxantrone. A review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185907/),h,8.9,240395,DB01204,Mitoxantrone
,2185907,terminal half-life,"In contrast, the values of the terminal half-life are quite variable, ranging from 8.9 hours to 9 days.",Pharmacokinetics and metabolism of mitoxantrone. A review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185907/),d,9,240396,DB01204,Mitoxantrone
,11884053,peritoneal peak concentrations,"On the 1st day, mean peritoneal peak concentrations of mitoxantrone resulted 1.45 +/-0.56 (range 0.48-1.9) and 1.9+/-0.85 (range 1.27-3.13) microg/ml in the 5-mg and 10-mg patients, respectively.",Intraperitoneal mitoxantrone: a feasibility and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11884053/),[μg] / [ml],1.45,240882,DB01204,Mitoxantrone
,11884053,peritoneal peak concentrations,"On the 1st day, mean peritoneal peak concentrations of mitoxantrone resulted 1.45 +/-0.56 (range 0.48-1.9) and 1.9+/-0.85 (range 1.27-3.13) microg/ml in the 5-mg and 10-mg patients, respectively.",Intraperitoneal mitoxantrone: a feasibility and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11884053/),[μg] / [ml],1.9,240883,DB01204,Mitoxantrone
,11884053,dial,Mean dialysate/plasma exposure (AUC) ratio was 115.,Intraperitoneal mitoxantrone: a feasibility and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11884053/),,115,240884,DB01204,Mitoxantrone
,11884053,maximum tolerated total dose,"Even in patients with sutures, early post-operative fractionated intraperitoneal mitoxantrone appears feasible and safe, with a high local advantage, for up to 5 days of treatment and a maximum tolerated total dose of 20-25 mg/m(2).",Intraperitoneal mitoxantrone: a feasibility and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11884053/),[mg] / [m(2],20-25,240885,DB01204,Mitoxantrone
,2013113,transfer rate,"For liposomal MTO a transfer rate of 48% was determined, whereas 75.8% of free MTO was bound to the plasma proteins.","Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013113/),%,48,241475,DB01204,Mitoxantrone
,2013113,terminal elimination halflives,The terminal elimination halflives in the liver were 77 h for liposomal MTO and 14.4 h for free MTO.,"Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013113/),h,77,241476,DB01204,Mitoxantrone
,2013113,terminal elimination halflives,The terminal elimination halflives in the liver were 77 h for liposomal MTO and 14.4 h for free MTO.,"Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013113/),h,14.4,241477,DB01204,Mitoxantrone
,2013113,LD25,The LD25 of PA-MTO liposomes in mice was 19.6 mg/kg and that of free MTO was 7.7 mg/kg.,"Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013113/),[mg] / [kg],19.6,241478,DB01204,Mitoxantrone
,2013113,LD25,The LD25 of PA-MTO liposomes in mice was 19.6 mg/kg and that of free MTO was 7.7 mg/kg.,"Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013113/),[mg] / [kg],7.7,241479,DB01204,Mitoxantrone
,8890711,half-life,"Recent pharmacokinetic studies have revealed a prolonged release of the cytotoxic agent cytosine arabinoside (araC) from hepatocytes into the systemic circulation, resulting in a half-life of approximately 24 h for araC.","Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8890711/),h,24,241594,DB01204,Mitoxantrone
,32357395,IC50,"The transcellular efflux of prazosin, a stereotypical BCRP substrate, was also significantly reduced in the presence of quercetin in a bidirectional transport assay using human BCRP-overexpressing cells; further kinetic analysis revealed IC50 and Ki values of 4.22 and 3.91 μM, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),μM,4.22,244361,DB01204,Mitoxantrone
,32357395,Ki,"The transcellular efflux of prazosin, a stereotypical BCRP substrate, was also significantly reduced in the presence of quercetin in a bidirectional transport assay using human BCRP-overexpressing cells; further kinetic analysis revealed IC50 and Ki values of 4.22 and 3.91 μM, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),μM,3.91,244362,DB01204,Mitoxantrone
,32357395,AUC8h,"Moreover, pretreatment with 10 mg/kg quercetin in rats led to a 1.8-fold and 1.5-fold increase in the AUC8h (i.e., 44.5 ± 11.8 min∙μg/mL vs. 25.7 ± 9.98 min∙μg/mL, p < 0.05) and Cmax (i.e., 179 ± 23.0 ng/mL vs. 122 ± 23.2 ng/mL, p < 0.05) of orally administered sulfasalazine, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),[min∙μg] / [ml],44.5,244363,DB01204,Mitoxantrone
,32357395,AUC8h,"Moreover, pretreatment with 10 mg/kg quercetin in rats led to a 1.8-fold and 1.5-fold increase in the AUC8h (i.e., 44.5 ± 11.8 min∙μg/mL vs. 25.7 ± 9.98 min∙μg/mL, p < 0.05) and Cmax (i.e., 179 ± 23.0 ng/mL vs. 122 ± 23.2 ng/mL, p < 0.05) of orally administered sulfasalazine, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),[min∙μg] / [ml],25.7,244364,DB01204,Mitoxantrone
,32357395,Cmax,"Moreover, pretreatment with 10 mg/kg quercetin in rats led to a 1.8-fold and 1.5-fold increase in the AUC8h (i.e., 44.5 ± 11.8 min∙μg/mL vs. 25.7 ± 9.98 min∙μg/mL, p < 0.05) and Cmax (i.e., 179 ± 23.0 ng/mL vs. 122 ± 23.2 ng/mL, p < 0.05) of orally administered sulfasalazine, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),[ng] / [ml],179,244365,DB01204,Mitoxantrone
,32357395,Cmax,"Moreover, pretreatment with 10 mg/kg quercetin in rats led to a 1.8-fold and 1.5-fold increase in the AUC8h (i.e., 44.5 ± 11.8 min∙μg/mL vs. 25.7 ± 9.98 min∙μg/mL, p < 0.05) and Cmax (i.e., 179 ± 23.0 ng/mL vs. 122 ± 23.2 ng/mL, p < 0.05) of orally administered sulfasalazine, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),[ng] / [ml],122,244366,DB01204,Mitoxantrone
,7083236,first-phase half-life,"Pharmacokinetic studies employing a fluorometric assay based on DNA binding measured by displacement of ethidium bromide revealed a first-phase half-life of about 15 minutes, with a prolonged subsequent phase.",Clinical and clinical pharmacologic studies of mitoxantrone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083236/),min,15,246765,DB01204,Mitoxantrone
,2344886,survival,Median survival was 6 months for all patients and 10 months for responders.,High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2344886/),month,6,250407,DB01204,Mitoxantrone
,2344886,survival,Median survival was 6 months for all patients and 10 months for responders.,High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2344886/),,10,250408,DB01204,Mitoxantrone
,3327453,Remission rates,Remission rates of between 24 and 54% were achieved by single-drug treatment in pretreated patients suffering from non-Hodgkin lymphoma.,"Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327453/),%,24 and 54,252648,DB01204,Mitoxantrone
,8127148,Plasma AUC infinity,Plasma AUC infinity for mitoxantrone differed approximately 13-fold between individual patients and varied between 80-1030 ngh/ml.,New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8127148/),[ngh] / [ml],80-1030,256808,DB01204,Mitoxantrone
,8127148,terminal half-life,The median terminal half-life for mitoxantrone was similar to that of the mono- and dicarboxylic acid and was 75 h.,New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8127148/),h,75,256809,DB01204,Mitoxantrone
,8127148,Cumulative renal elimination,"Cumulative renal elimination ranged from 670-1950 micrograms for mitoxantrone, from 366-852 micrograms for monocarboxylic acid, and from 792-3420 micrograms for dicarboxylic acid.",New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8127148/),μg,670-1950,256810,DB01204,Mitoxantrone
,8127148,Cumulative renal elimination,"Cumulative renal elimination ranged from 670-1950 micrograms for mitoxantrone, from 366-852 micrograms for monocarboxylic acid, and from 792-3420 micrograms for dicarboxylic acid.",New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8127148/),μg,366-852,256811,DB01204,Mitoxantrone
,8127148,Cumulative renal elimination,"Cumulative renal elimination ranged from 670-1950 micrograms for mitoxantrone, from 366-852 micrograms for monocarboxylic acid, and from 792-3420 micrograms for dicarboxylic acid.",New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8127148/),μg,792-3420,256812,DB01204,Mitoxantrone
,8127148,Renal clearance,Renal clearance of mitoxantrone reached a median level of 69 ml/min and for the total plasma clearance a median of 1136 ml/min was found.,New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8127148/),[ml] / [min],69,256813,DB01204,Mitoxantrone
,8127148,total plasma clearance,Renal clearance of mitoxantrone reached a median level of 69 ml/min and for the total plasma clearance a median of 1136 ml/min was found.,New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8127148/),[ml] / [min],1136,256814,DB01204,Mitoxantrone
,3568271,terminal half-life (t 1/2 gamma),"Plasma levels of ametantrone declined in a triexponential fashion, with a mean terminal half-life (t 1/2 gamma) of 25 h.",Pharmacokinetics of ametantrone acetate (NSC-287513). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568271/),h,25,257665,DB01204,Mitoxantrone
,3568271,total-body plasma clearance,The estimated mean total-body plasma clearance was 25.9 +/- 14.7 1 h-1 m-2.,Pharmacokinetics of ametantrone acetate (NSC-287513). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568271/),[1] / [(m)^2·h],25.9,257666,DB01204,Mitoxantrone
,3568271,steady-state volume of distribution (Vdss),"The steady-state volume of distribution (Vdss) was large, averaging 568 +/- 630 l/m2.",Pharmacokinetics of ametantrone acetate (NSC-287513). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568271/),[l] / [m2],568,257667,DB01204,Mitoxantrone
,3167842,time product,"time product of 100 micrograms.h/ml in the i.p. space and of 0.071 micrograms.h/ml in plasma, yielding an i.p./plasma area under the curve ratio of 1408.",Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3167842/),[h·μg] / [ml],100,258725,DB01204,Mitoxantrone
,3167842,time product,"time product of 100 micrograms.h/ml in the i.p. space and of 0.071 micrograms.h/ml in plasma, yielding an i.p./plasma area under the curve ratio of 1408.",Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3167842/),[h·μg] / [ml],0.071,258726,DB01204,Mitoxantrone
,3167842,area under the curve ratio,"time product of 100 micrograms.h/ml in the i.p. space and of 0.071 micrograms.h/ml in plasma, yielding an i.p./plasma area under the curve ratio of 1408.",Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3167842/),,1408,258727,DB01204,Mitoxantrone
,3546616,peak plasma mitoxantrone concentration,"Neither clinical response nor toxicity was strongly correlated with the peak plasma mitoxantrone concentration on the first day (mean +/- SD, 510 +/- 206 ng/mL), nor the area under the concentration-time curve (484 +/- 229 ng X h/mL), nor the systemic clearance (405 +/- 124 mL/min/m2).",A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3546616/),[ng] / [ml],510,259704,DB01204,Mitoxantrone
,3546616,area under the concentration-time curve,"Neither clinical response nor toxicity was strongly correlated with the peak plasma mitoxantrone concentration on the first day (mean +/- SD, 510 +/- 206 ng/mL), nor the area under the concentration-time curve (484 +/- 229 ng X h/mL), nor the systemic clearance (405 +/- 124 mL/min/m2).",A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3546616/),[h·ng] / [ml],484,259705,DB01204,Mitoxantrone
,3546616,systemic clearance,"Neither clinical response nor toxicity was strongly correlated with the peak plasma mitoxantrone concentration on the first day (mean +/- SD, 510 +/- 206 ng/mL), nor the area under the concentration-time curve (484 +/- 229 ng X h/mL), nor the systemic clearance (405 +/- 124 mL/min/m2).",A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3546616/),[ml] / [m2·min],405,259706,DB01204,Mitoxantrone
,24036845,AUC,Only small variations were observed in the corresponding plasma AUC (2.9-5 μM h).,"Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036845/),h·μM,2.9-5,269421,DB01204,Mitoxantrone
,22511498,complete remission,"Significantly higher complete remission rates were observed in female patients (86 vs. 47%; Odds Ratio 6.8, 95% CI: 1.12; 41.82; P=0.05).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),,86,269684,DB01204,Mitoxantrone
,22511498,complete remission,"Significantly higher complete remission rates were observed in female patients (86 vs. 47%; Odds Ratio 6.8, 95% CI: 1.12; 41.82; P=0.05).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),,47,269685,DB01204,Mitoxantrone
,22511498,area under the curve,"Rituximab pharmacokinetic analysis showed a high variability ranging over almost 1 order of magnitude at maintenance cycle 1 (area under the curve 1,540-12,025 g/L*days).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),[g] / [d·l],"1,540-12,025",269686,DB01204,Mitoxantrone
below,22511498,C(trough),"A decline in rituximab C(trough) below 25,000 ng/mL was observed 9.5 to 62 months before clinical relapse (P=0.008).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),[ng] / [ml],"25,000",269687,DB01204,Mitoxantrone
,15020609,disease-free survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,10,270463,DB01204,Mitoxantrone
,15020609,disease-free survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,9.3,270464,DB01204,Mitoxantrone
,15020609,overall survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,4.6,270465,DB01204,Mitoxantrone
,15020609,overall survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,5.4,270466,DB01204,Mitoxantrone
,15020609,CR rates,The CR rates in MDR+ (69% of patients) versus MDR- patients were similar for those receiving either chemotherapy regimen (16% versus 24%).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),%,16,270467,DB01204,Mitoxantrone
,15020609,CR rates,The CR rates in MDR+ (69% of patients) versus MDR- patients were similar for those receiving either chemotherapy regimen (16% versus 24%).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),,24,270468,DB01204,Mitoxantrone
,15020609,CR rate,"The CR rate for unfavorable cytogenetic patients (45% of patients) was 13% compared to the remainder, 28% (P=.09).","Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),%,13,270469,DB01204,Mitoxantrone
